Related references
Note: Only part of the references are listed.High Density Lipoprotein Cholesterol and the Risk of All-Cause Mortality among US Veterans
Benjamin Bowe et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2016)
Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cut-points-a joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine
Borge G. Nordestgaard et al.
EUROPEAN HEART JOURNAL (2016)
2016 European Guidelines on cardiovascular disease prevention in clinical practice
Massimo F. Piepoli et al.
EUROPEAN HEART JOURNAL (2016)
Change in Body Mass Index Associated With Lowest Mortality in Denmark, 1976-2013
Shoaib Afzal et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
High-Density Lipoprotein Cholesterol and Cause-Specific Mortality in Individuals Without Previous Cardiovascular Conditions The CANHEART Study
Dennis T. Ko et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2016)
Rare variant in scavenger receptor BI raises HDL cholesterol and increases risk of coronary heart disease
Paolo Zanoni et al.
SCIENCE (2016)
Loss-of-Function Mutations in APOC3 and Risk of Ischemic Vascular Disease
Anders Berg Jorgensen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117 411 patients
Daniel Keene et al.
BMJ-BRITISH MEDICAL JOURNAL (2014)
Coronary Heart Disease Risks Associated with High Levels of HDL Cholesterol
John T. Wilkins et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2014)
Evidence of a Polygenic Origin of Extreme High-Density Lipoprotein Cholesterol Levels-Brief Report
Mohammad Mahdi Motazacker et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2013)
Remnant Cholesterol as a Causal Risk Factor for Ischemic Heart Disease
Anette Varbo et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2013)
Genetic Inhibition of CETP, Ischemic Vascular Disease and Mortality, and Possible Adverse Effects
Trine Holm Johannsen et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2012)
The Effect of Elevated Body Mass Index on Ischemic Heart Disease Risk: Causal Estimates from a Mendelian Randomisation Approach
Borge G. Nordestgaard et al.
PLOS MEDICINE (2012)
Major Lipids, Apolipoproteins, and Risk of Vascular Disease
The Emerging Risk Factors Collaboration*
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2009)
Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies
Rajesh Krishna et al.
LANCET (2007)
Effects of torcetrapib in patients at high risk for coronary events
Philip J. Barter et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women
Borge G. Nordestgaard et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2007)
Hepatic lipase mutations, elevated high-density lipoprotein cholesterol, and increased risk of ischemic heart disease -: The Copenhagen City Heart Study
RV Andersen et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2003)
Elevated HDL cholesterol is a risk factor for ischemic heart disease in white women when caused by a common mutation in the cholesteryl ester transfer protein gene
B Agerholm-Larsen et al.
CIRCULATION (2000)
Share Paper
